How rAAV genome sequencing uncovers transgene integrity

Gene sequence

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies.

The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden, and Bastian Schiffthaler, Senior Data Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden.

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will detail how Oxford Nanopore evaluated long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs which is supporting internal research activities at AstraZeneca. Information will be presented on how they performed library preparation, assessed data quality, and generated important rAAV metrics such as integrity of DNA cargo, truncation events, chimeric transgenes, and levels of co-packaged impurities.

The event will take place on 13 May, 4PM BST.

What you will learn:

  1. Raw material validation through whole plasmid sequencing
  2. ITR-ITR sequencing of whole AAV genomes and truncation hotspot detection
  3. Contamination detection in bioreactor batches through sequencing of residual DNA

Register for free here.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free